Advocacy intelligence hub — real-time data for patient organizations
M.D. Anderson Cancer Center — PHASE1
Institute of Hematology & Blood Diseases Hospital, China — EARLY_PHASE1
Beijing GoBroad Hospital — PHASE1, PHASE2
Shanghai Jiao Tong University School of Medicine — EARLY_PHASE1
Goethe University — PHASE2
First Affiliated Hospital of Zhejiang University — PHASE3
Iclusig: FDA approved
treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
The First Affiliated Hospital of Soochow University — EARLY_PHASE1
Assistance Publique - Hôpitaux de Paris
COPIKTRA: FDA approved
Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Patient Assistance Programs6
Arranon
Novartis Pharmaceuticals Corp.
Clolar
Genzyme Corporation
Iclusig
Takeda Pharmaceuticals U.S.A., Inc.
Blincyto
Amgen, Inc.
TECARTUS�
Kite Pharma, Inc.
Aucatzyl
Autolus Incorporated, US subsidiary of Autolus Limited
Iclusig
(ponatinib)Orphan drugTakeda Pharmaceuticals U.S.A., Inc.
12.1 Mechanism of Action Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with I...
COPIKTRA
(duvelisib)Orphan drugSecura Bio, Inc.
12.1 Mechanism of Action Duvelisib is an inhibitor of PI3K with inhibitory activity predominantly against PI3K-δ and PI3K-γ isoforms expressed in norm...
Kymriah (tisagenlecleucel)
((tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19)Orphan drugNovartis Pharmaceuticals Corporation
Vumon for injection
(Teniposide)Orphan drugBristol-Myers Squibb Pharmaceutical Research Institute
TECARTUS�
(brexucabtagene autoleucel)Orphan drugstandardKite Pharma, Inc.
12.1 Mechanism of Action TECARTUS, a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and nor...
Marqibo
(vinCRIStine sulfate LIPOSOME injection)Orphan drugstandardAcrotech Biopharma LLC
Kymriah
(tisagenlecleucel)Orphan drugstandardNovartis Pharmaceuticals Corporation
CD19-directed Chimeric Antigen Receptor [EPC]
12.1 Mechanism of Action KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy which involves reprogramming a patient’s own ...
Blincyto
(blinatumomab)Orphan drugstandardAmgen, Inc.
12.1 Mechanism of Action Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-linea...
Browse all Precursor T-cell acute lymphoblastic leukemia news →
Prof. Dr. Michael Schmitt
University Hospital Heidelberg, Department V
Prof. Dr. Andreas Kulozik
University Hospital Heidelberg, University Medical Center for Children and Adolescents
Paolo Caimi, MD, M.D
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
📍 CLEVELAND, OH
Robert Lowsky, MD, MD
Stanford Medical Center
📍 STANFORD, CA
Thomas G. Martin, MD
University of California, San Francisco
Yue-jun Liu
The First Affiliated Hospital of Soochow University
View all Precursor T-cell acute lymphoblastic leukemia specialists →